ALK inhibitors have proved an efficacious modality for targeted cancer therapy [46] since the launch of crizotinib in 2011 for the clinical treatment of ALK-positive non-small cell lung cancer (NSCLC) [47]. This evidence concerns the gene ALK and cancer.